Active, not recruitingPhase 2NCT07013565
Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL
Studying ALK-negative anaplastic large cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- New York Medical College
- Principal Investigator
- Mitchell S Cairo, MDNew York Medical College
- Intervention
- Vinblastine (Velban)(drug)
- Enrollment
- 20 enrolled
- Eligibility
- 1-39 years · All sexes
- Timeline
- 2025 – 2030
Study locations (1)
- New York Medical College, Valhalla, New York, United States
Collaborators
University of Alabama at Birmingham · Helen DeVos Children's Hospital · Nationwide Children's Hospital · Memorial Sloan Kettering Cancer Center · University of Utah · Ohio State University · University of North Carolina · Children's Hospital of Philadelphia · Medical College of Wisconsin · Children's Hospital of Orange County
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07013565 on ClinicalTrials.govOther trials for ALK-negative anaplastic large cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07300514Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell LymphomaFudan University
- RECRUITINGPHASE2NCT07356245Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaJonathan Brammer
- RECRUITINGPHASE1NCT06176690Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive LymphomasBaylor College of Medicine
- RECRUITINGPHASE1NCT07001384A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)Memorial Sloan Kettering Cancer Center
- RECRUITINGPHASE2NCT05996185Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell LymphomaYale University
- RECRUITINGPHASE1NCT06508463Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaMayo Clinic
- RECRUITINGPHASE1, PHASE2NCT04925609Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid TumorsPrincess Maxima Center for Pediatric Oncology
- ACTIVE NOT RECRUITINGPHASE4NCT05160922Crizotinib Continuation Clinical StudyPfizer
See all trials for ALK-negative anaplastic large cell lymphoma →